[A24-33] Niraparib/abiraterone acetate (prostate cancer) – Addendum to Project A23-107
Last updated 02.05.2024
Project no.:
A24-33
Commission:
Commission awarded on 26.05.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with metastatic castration-resistant prostate cancer (mCRPC) and breast cancer susceptibility gene 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated
- Patients with treatment-naive mCRPC without prior taxane-containing chemotherapy: Unchanged after addendum: hint of considerable added benefit
- Patients with treatment-naive mCRPC with prior taxane-containing chemotherapy: After addendum now: hint of minor added benefit
- Patients with pretreated mCRPC: Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A24-33_en
| Project no. | Title | Status |
|---|---|---|
| A23-107 | Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-05-02 A G-BA decision was published.